Grindeks forecasts $17 million earning this year
This article was originally published in Scrip
Latvia's largest pharmaceutical manufacturer Grindeks has forecasted Lt10 million ($17.2 million) annual earnings this year on the grounds of successive sales in the first five months. It said it has already achieved significant sales growth in the first five months in Latvia (+30%) and several foreign markets including Moldova (+66%), Ukraine (+30%) and Kazakhstan (+18%).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.